Core Viewpoint - Mirxes Holding Company Limited is seeking to list on the Hong Kong Stock Exchange, with CICC and CCB International as joint sponsors [1] Company Overview - Founded in 2014, Mirxes is a Singapore-based company specializing in microRNA (miRNA) technology aimed at making disease screening and diagnostic solutions accessible in key Asian markets, including Singapore and China [3] - The company has one core product, GASTROClearTM, which is the world's first and only approved molecular diagnostic IVD product for gastric cancer screening [3] Market Opportunity - Gastric cancer is the fifth leading cause of cancer death globally in 2023, with approximately 1 million new cases [3] - The gastric cancer screening market in China, Japan, Southeast Asia, and the United States grew from $13 billion in 2019 to $15.2 billion in 2023, with a compound annual growth rate (CAGR) of 4.1% [3] - The market is projected to reach $21.2 billion by 2028 and $25.4 billion by 2033, with CAGRs of 6.8% and 3.7% respectively for the periods 2023-2028 and 2028-2033 [3] Financial Performance - Revenue for 2022, 2023, and 2024 is estimated at approximately $17.76 million, $24.19 million, and $20.28 million respectively [4] - Gross profit for the same years is estimated at about $9.33 million, $13.58 million, and $8.89 million [4] - The company has incurred significant operating losses, with a projected loss of approximately $56.2 million in 2022, $69.57 million in 2023, and $92.21 million in 2024 [6]